A wellness platform with about 15,000 customers made over $5 million in sales so far in 2026. BHIC agreed to buy 40%.
BioScience Health Innovations, Inc. (BHIC) agreed to acquire 40% of a wellness platform with 15,000 customers and $5M in 2026 sales, and 100% of Vitalcore, a hair-growth tech company. BHIC will issue 450,000 restricted shares for the transactions, aiming to expand its health and wellness portfolio.
How this was made
The 30-second read
Why it matters
The acquisitions provide BHIC with proprietary hair‑growth technology and direct access to a 15,000‑customer wellness platform, potentially accelerating revenue growth while introducing share dilution.
Market read
Primary M&A disclosure for a micro‑cap health‑wellness firm; modest but actionable impact for traders monitoring OTC biotech and consumer‑wellness stocks.
What to watch
Regulatory approvals for hair‑growth claims and integration risk of Vitalcore may delay value realization.
Background
BioScience Health Innovations (BHIC) is a diversified health‑wellness company operating the Best365Labs platform. It disclosed two strategic transactions to broaden its product portfolio.
Ticker impact
BHIC announced the acquisition of Vitalcore and a 40% stake in a peptide and wellness platform, issuing 450,000 restricted shares as consideration.
likely modest upside as investors price in growth potential versus dilution from share issuance
First‑report M&A adds tangible assets; market typically rewards expansion, though dilution tempers the move.
Market effects
strengthens the health‑wellness and hair‑growth niche, may spur interest in peer biotech and consumer‑wellness stocks
U.S. OTC market sees modest activity; limited broader market effect
low
Counterpoint
Dilution from 450k restricted shares could outweigh growth benefits, leading to short‑term pressure.
Key entities
- companyBioScience Health Innovations, Inc.
Issuer of the announced acquisitions.
- companyVitalcore
Target of 100% acquisition for hair‑growth technology.
- companyAgeless Holdings, LLC
Seller of the 40% stake in the peptide and wellness platform.



